within Pharmacolibrary.Drugs.ATC.B;

model B05AA07
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006016666666666667,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00591,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00521,
    k12             = 8.14,
    k21             = 8.14
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05AA07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Hydroxyethyl starch (HES) is a synthetic colloid used as a plasma volume expander to treat or prevent hypovolemia, commonly during surgery, trauma, or in intensive care. It acts by increasing the oncotic pressure in the bloodstream. Its use has declined in recent years due to safety concerns regarding coagulopathy and renal toxicity, and it is restricted or withdrawn in some regions.</p><h4>Pharmacokinetics</h4><p>Reported for healthy male volunteers (mean age ~23 years), single intravenous infusion of hydroxyethyl starch 130/0.4 (Voluven)</p><h4>References</h4><ol><li><p>Weisshaar, E, et al., &amp; Zenk, J (2009). [Hydroxyethylstarch-induced pruritus: an understimated side effect of its application also in ENT diseases]. <i>Laryngo- rhino- otologie</i> 88(9) 604–611. DOI:<a href=&quot;https://doi.org/10.1055/s-0029-1237393&quot;>10.1055/s-0029-1237393</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19711242/&quot;>https://pubmed.ncbi.nlm.nih.gov/19711242</a></p></li><li><p>Okutomi, T, et al., &amp; Kuczkowski, KM (2006). The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. <i>Acta anaesthesiologica Belgica</i> 57(3) 259–264. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17067137/&quot;>https://pubmed.ncbi.nlm.nih.gov/17067137</a></p></li><li><p>Jungheinrich, C, et al., &amp; Baron, JF (2002). The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. <i>Anesthesia and analgesia</i> 95(3) 544–None. DOI:<a href=&quot;https://doi.org/10.1097/00000539-200209000-00007&quot;>10.1097/00000539-200209000-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12198032/&quot;>https://pubmed.ncbi.nlm.nih.gov/12198032</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05AA07;
